伴器官损害或威胁生命的ANCA相关性血管炎的治疗进展及挑战  

Challenges and Progress in the Treatment of Organ Damage Associated by ANCA or Life-threatening ANCA Associated Vasculitis

作　　者：何旭 夏正坤 HE Xu;XIA Zhengkun(Department of Pediatrics,Eastern theater General Hospital,Nanjing 210002,China)

机构地区：[1]东部战区总医院儿科,江苏省南京市210002

出　　处：《中国全科医学》2021年第23期2891-2897,共7页Chinese General Practice

基　　金：江苏省重点研发计划-临床前沿技术项目(BE2017719);江苏省儿科医学创新团队项目(CXTDA2017022)。

摘　　要：随着大量临床研究的开展和各国指南的发布,伴有器官损害或威胁生命的ANCA相关性血管炎(AAV)的治疗已经获得了重要突破,从致死性疾病转变为一类慢性疾病。利妥昔单抗(RTX)在AAV诱导和维持治疗中的作用获得了有力的循证医学支持,并最终纳入现行的大部分指南。AAV患者的长期预后不仅取决于血管炎疾病本身,还取决于长期用药带来的不良反应。因此,优化治疗药物、治疗剂量和治疗周期,减少药物的不良反应,最终改善生存率是未来临床研究的工作方向。With the development of a large number of clinical studies and the release of national guidelines,the treatment of organ damage associated by ANCA and ANCA associated vasculitis(AAV)has made an important breakthrough,transforming it from a fatal disease into a chronic disease.The role of rituximab(RTX)in induction and maintenance therapy has been strongly supported by evidence-based medicine and it has finally been included in most of the current guidelines.Optimizing treatment drugs,treatment doses and treatment cycles,reducing adverse drug reactions,and ultimately improving patient survival rates are the directions of future clinical research.

关 键 词：抗中性粒细胞胞浆抗体相关性血管炎 治疗 免疫抑制剂 利妥昔单抗 综述 指南 

分 类 号：R543[医药卫生—心血管疾病]